Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …

Objectives The prevalence and clinical outcomes of COVID-19 in patients with autoimmune
diseases who are frequently treated with disease modifying therapies remains poorly …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Background Data are needed to inform the positioning of biologic therapy in the treatment of
moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We …

Almost all currently available treatments for inflammatory bowel disease (IBD) act by
inhibiting inflammation, often blocking specific inflammatory molecules. However, given the …

The current coronavirus pandemic is an ongoing global health crisis due to COVID-19,
caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to …

The exciting success of NBTXR3 in the clinic has triggered a tumult of activities in the design
and development of hafnium-based nanoparticles. However, due to the concerns of …

Background The COVID-19 pandemic has continued to cause unprecedented concern
across the globe since the beginning of the outbreak. Healthcare workers, particularly those …

Im Jahr 2019 wurden etwa 25 500 Patient* innen mit M. Crohn im Krankenhaus stationär
behandelt [1]. Meistens tritt die Erkrankung in der Adoleszenz und im jungen …